Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

Clinical trial NCT03566485 · TERMINATED

Trial details

NCT number: NCT03566485
Sponsor: Vanderbilt-Ingram Cancer Center
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Stage III Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Estrogen Receptor-positive HER2/Neu Negative

Start date: 2018-07-10
Primary completion: 2020-12-10
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.